Profile data is unavailable for this security.
About the company
LePU Biopharma Co Ltd is a China-based biopharmaceutical company focused on tumor treatment. The Company mainly develops product lines of tumor candidate drugs, including antibody drug conjugate (ADC), oncolytic virus drug products and immunotherapy at clinical and pre-clinical stages. The Company’s major pipeline assets consist of MRG003, MRG002, HX008 and LP002, and three key clinical-stage drug candidates. The Company's products are sold at home and abroad.
- Revenue in HKD (TTM)220.56m
- Net income in HKD-78.10m
- Incorporated2018
- Employees491.00
- LocationLepu Biopharma Co LtdNo. 651, Lianheng Road, Minhang DistrictSHANGHAI 201114ChinaCHN
- Phone+86 2 167696099
- Websitehttps://www.lepubiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qyuns Therapeutics Co Ltd | 48.31m | -453.64m | 2.89bn | 325.00 | -- | 7.30 | -- | 59.76 | -1.93 | -1.93 | 0.2193 | 1.78 | -- | -- | -- | 145,950.60 | -- | -- | -- | -- | 84.05 | -- | -976.77 | -- | 1.83 | -29.56 | 0.5795 | -- | -- | -- | -70.28 | -- | -- | -- |
| Abbisko Cayman Ltd | 534.81m | -17.42m | 3.02bn | 275.00 | -- | 1.36 | 850.57 | 5.65 | -0.0295 | -0.0295 | 0.8235 | 3.28 | 0.2159 | -- | 65.75 | 2,072,904.00 | -0.7034 | -- | -0.733 | -- | 0.00 | -- | -3.26 | -- | -- | -- | 0.0142 | -- | -- | -- | 12.92 | -- | -- | -- |
| ImmuneOnco Biopharmaceuticls Shanghi Inc | 405.46k | -402.65m | 3.17bn | 150.00 | -- | 4.91 | -- | 7,816.15 | -1.12 | -1.12 | 0.0011 | 1.73 | -- | -- | -- | 2,796.26 | -- | -- | -- | -- | -- | -- | -99,307.43 | -- | -- | -- | 0.14 | -- | -28.25 | -- | 5.82 | -- | -- | -- |
| CARsgen Therapeutics Holdings Ltd | 6.82m | -747.33m | 4.17bn | 477.00 | -- | 2.61 | -- | 611.06 | -1.34 | -1.34 | 0.0122 | 2.80 | 0.0027 | -- | 0.302 | 13,214.28 | -29.27 | -- | -32.86 | -- | 25.50 | -- | -10,960.25 | -- | 9.44 | -- | 0.1246 | -- | -- | -- | 16.19 | -- | -- | -- |
| Alphamab Oncology | 275.18m | -231.90m | 4.33bn | 429.00 | -- | 2.48 | -- | 15.74 | -0.2409 | -0.2409 | 0.2858 | 1.82 | 0.1145 | 0.8256 | 13.94 | 632,607.10 | -9.65 | -18.72 | -11.16 | -21.94 | 79.33 | -- | -84.27 | -415.55 | 4.42 | -- | 0.167 | -- | 31.12 | -- | 35.35 | -- | -13.12 | -- |
| Laekna Inc | 0.00 | -317.84m | 4.44bn | 92.00 | -- | 6.10 | -- | -- | -0.8919 | -0.8919 | 0.00 | 1.86 | 0.00 | -- | -- | 0.00 | -31.46 | -- | -35.71 | -- | -- | -- | -- | -- | -- | -- | 0.0856 | -- | -- | -- | 52.81 | -- | -- | -- |
| Lepu Biopharma Co Ltd | 220.56m | -78.10m | 5.53bn | 491.00 | -- | 5.62 | 405.74 | 25.05 | -0.0463 | -0.0463 | 0.1325 | 0.5751 | 0.0847 | 1.86 | 1.53 | 514,131.50 | -3.53 | -- | -5.72 | -- | 78.76 | -- | -41.62 | -- | 0.7322 | -2.71 | 0.4621 | -- | 1,347.16 | -- | 96.79 | -- | -- | -- |
Data as of Nov 14 2024. Currency figures normalised to Lepu Biopharma Co Ltd's reporting currency: Hong Kong Dollar HKD
3.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 22.04m | 1.33% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 7.53m | 0.46% |
| Essence Fund Co., Ltd.as of 30 Jun 2024 | 6.30m | 0.38% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 5.67m | 0.34% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2024 | 5.35m | 0.32% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 4.34m | 0.26% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 4.17m | 0.25% |
| Huashang Fund Management Co., Ltd.as of 30 Jun 2024 | 3.79m | 0.23% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 3.57m | 0.22% |
| Baoying Fund Management Co., Ltd.as of 30 Jun 2024 | 3.31m | 0.20% |
More ▼
Data from 30 Jun 2024 - 29 Oct 2024Source: FactSet Research Systems Inc.
